Amplify Weight Loss Drug & Treatment ETF (THNR)
| Assets | $5.28M |
| Expense Ratio | 0.59% |
| PE Ratio | 20.00 |
| Shares Out | 200,000 |
| Dividend (ttm) | $0.41 |
| Dividend Yield | 1.61% |
| Ex-Dividend Date | Dec 30, 2025 |
| Payout Frequency | Annual |
| Payout Ratio | 31.77% |
| Volume | 137 |
| Open | 25.70 |
| Previous Close | 26.00 |
| Day's Range | 25.70 - 25.70 |
| 52-Week Low | 22.63 |
| 52-Week High | 27.94 |
| Beta | 0.40 |
| Holdings | 22 |
| Inception Date | May 21, 2024 |
About THNR
Fund Home PageThe Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.
Top 10 Holdings
62.04% of assets| Name | Symbol | Weight |
|---|---|---|
| Novo Nordisk A/S | NVO | 9.25% |
| Eli Lilly and Company | LLY | 9.08% |
| Regeneron Pharmaceuticals, Inc. | REGN | 6.13% |
| Innovent Biologics, Inc. | 1801 | 5.85% |
| CSPC Pharmaceutical Group Limited | 1093 | 5.54% |
| Amgen Inc. | AMGN | 5.48% |
| Scholar Rock Holding Corporation | SRRK | 5.36% |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 5.19% |
| Roche Holding AG | ROP | 5.11% |
| Merck & Co., Inc. | MRK | 5.07% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 30, 2025 | $0.41317 | Dec 31, 2025 |
| Dec 30, 2024 | $0.2199 | Dec 31, 2024 |
Performance
THNR had a total return of 13.49% in the past year, including dividends. Since the fund's inception, the average annual return has been 2.10%.
News
SILJ, HACK, THNR: Trends in Thematic Investing
Amplify Junior Silver Miners ETF (SILJ) is up 28% year-to-date. Christian Magoon discusses the outlook for cybersecurity stocks, as Amplify's Cybersecurity ETF (HACK) is up 8% year-to-date.
Why Investors Haven't Feasted on Two New Weight-Loss ETFs
Two new weight-loss exchange-traded funds (ETFs) launched in May have yet to whet investors' appetite, possibly due to their expensive fees and concentrated bets.